Fri, October 29, 2010
Thu, October 28, 2010
Wed, October 27, 2010
Tue, October 26, 2010
Mon, October 25, 2010
Sun, October 24, 2010
Sat, October 23, 2010
Fri, October 22, 2010
Thu, October 21, 2010
Wed, October 20, 2010
[ Wed, Oct 20th 2010 ]: Market Wire
STJ, AGAM, BAC, MDT, BSX
Tue, October 19, 2010
Mon, October 18, 2010
Sun, October 17, 2010
Sat, October 16, 2010
Fri, October 15, 2010
[ Fri, Oct 15th 2010 ]: Market Wire
ALGN, FCN, GOOG, SWY, GCI
Thu, October 14, 2010
Wed, October 13, 2010
Tue, October 12, 2010

Apricus Biosciences to Present at the FSX Investor Conference in Phoenix, AZ on October 29, 2010


  Copy link into your clipboard //health-fitness.news-articles.net/content/2010/ .. conference-in-phoenix-az-on-october-29-2010.html
  Print publication without navigation Published in Health and Fitness on by Market Wire


SAN DIEGO--([ BUSINESS WIRE ])--Apricus Biosciences (aApricus Bioa) (Nasdaq: APRI) today announced that Bassam Damaj, Ph.D., President and Chief Executive Officer, will present at the FSX (Financial Services Exchange, Inc.) investors conference being held at the Ritz Carlton in Phoenix, AZ from October 28-30, 2010. Dr. Damaja™s presentation is scheduled for Friday morning, October 29, 2010. The event is not being webcast.

FSX is the premier investment conference organization in the United States, hosting quarterly investment conferences around the country, providing opportunities for networking and one-on-one communication between independent broker/dealers and companies seeking exposure or funding. FSX conferences also provide a forum for direct investment programs, mutual funds, and asset management companies. For more information visit: [ www.fsxone.com ].

About Apricus Biosciences

Backed by NexMed, USA and Bio-Quant, Inc., its revenue generating CRO business, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on Apricus Bio and its subsidiaries, visit [ http://www.apricusbio.com ].


Publication Contributing Sources

Publication Sponsors
[ Last Sunday ] - Oceanside Rental Gear